11:48 AM EST - Arch Biopartners, Inc. : Has engaged Catalent Inhalation, a division of Catalent Pharma Solutions, to begin the manufacturing process for its drug AB569 in preparation for the first human trials involving patients with antibiotic resistant lung infections. Arch Biopartners, Inc.
shares V.ACH are trading down $0.045 at $0.44.
